Join leaders in the biotechnology community as we gather in-studio at 805 Studios and online in our first hybrid event! Biotech is under pressure to produce miracle cures – yet access to finance, manufacturing challenges and increased regulations (like ESG) threaten the nascent industry, which employs thousands locally. Does biotech need our praise? Our scrutiny?Can biotech survive and thrive? And what about biotech’s supply chains and waste streams - sustainable? Guests include Patricia Turney, Chief Technical Officer, Acelyrin, Inc. (NASDAQ:SLRN) (former Arcutis and Amgen and US Navy); Michael Millar, Head of ESG, Deloitte; David Steinberg, former Senior Director of Facilities & Engineering, Atara Biotherapeutics (NASDAQ:ATRA) and Rita Norton, livestreamed from Washington, DC – former head of public affairs for Amgen, Roche and AmerisourceBergen. Join us in person or from where ever you are on livestream!